GOLD 2021 Strategy Report: Implications for Asthma–COPD Overlap

In its 2021 strategy report, the Global Initiative for Chronic Obstructive Lung Disease states: "we no longer refer to asthma-COPD overlap (ACO), instead we emphasize that asthma and COPD are different disorders, although they may [...] coexist in an individual patient. If a concurrent diagnosi...

Full description

Saved in:
Bibliographic Details
Published in:International journal of chronic obstructive pulmonary disease 2021-01, Vol.16, p.1709-1715
Main Authors: Roman-Rodriguez, Miguel, Kaplan, Alan
Format: Article
Language:English
Subjects:
Asthma
asthma–copd overlap
bronchodilator
Care and treatment
Chronic obstructive pulmonary disease
Confidence
copd
Diagnosis
inhaled corticosteroid
Patients
Physicians
Precision medicine
Primary care
Tiotropium
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In its 2021 strategy report, the Global Initiative for Chronic Obstructive Lung Disease states: "we no longer refer to asthma-COPD overlap (ACO), instead we emphasize that asthma and COPD are different disorders, although they may [...] coexist in an individual patient. If a concurrent diagnosis of asthma is suspected, pharmacotherapy should primarily follow asthma guidelines, but pharmacological and non-pharmacological approaches may also be needed for their COPD." What does this mean for the treating physician? In this review, we explore the implications of this new guidance on treating patients with chronic obstructive pulmonary disease, arguing for a personalized approach to treatment. Keywords: COPD, asthma, asthma-COPD overlap, inhaled corticosteroid, bronchodilator
ISSN:1178-2005
1176-9106
1178-2005
DOI:10.2147/COPD.S300902